Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase.
Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase.
复制标题
DOI:
10.1016/j.bcmd.2012.10.007
复制
发表时间:
2013-02
影响因子:
2.3
通讯作者:
Horowitz, Mia
中科院分区:
文献类型:
--
作者:
Bendikov-Bar, Inna;Maor, Gali;Filocamo, Mirella;Horowitz, Mia
Gaucher disease (GD) is characterized by accumulation of glucosylceramide in lysosomes due to mutations in the GBA1 gene encoding the lysosomal hydrolase β-glucocerebrosidase (GCase). The disease has a broad spectrum of phenotypes, which were divided into three different Types; Type 1 GD is not associated with primary neurological disease while Types 2 and 3 are associated with central nervous system disease. GCase molecules are synthesized on endoplasmic reticulum (ER)-bound polyribosomes, translocated into the ER and following modifications and correct folding, shuttle to the lysosomes. Mutant GCase molecules, which fail to fold correctly, undergo ER associated degradation (ERAD) in the proteasomes, the degree of which is one of the factors that determine GD severity. Several pharmacological chaperones have already been shown to assist correct folding of mutant GCase molecules in the ER, thus facilitating their trafficking to the lysosomes. Ambroxol, a known expectorant, is one such chaperone. Here we show that ambroxol increases both the lysosomal fraction and the enzymatic activity of several mutant GCase variants in skin fibroblasts derived from Type 1 and Type 2 GD patients.
登录
查看更多内容
影响因子:
3.7
作者:
Goldin E;Zheng W;Motabar O;Southall N;Choi JH;Marugan J;Austin CP;Sidransky E
通讯作者:
Sidransky E
影响因子:
3.5
作者:
Ron, I;Horowitz, M
通讯作者:
Horowitz, M
影响因子:
3.8
作者:
Babajani, Gholamreza;Tropak, Michael B.;Kermode, Allison R.
通讯作者:
Kermode, Allison R.
影响因子:
7.3
作者:
Goddard-Borger, Ethan D.;Tropak, Michael B.;Withers, Stephen G.
通讯作者:
Withers, Stephen G.
影响因子:
3.6
作者:
Colombeau, Ludovic;Traore, Tenin;Martin, Olivier R.
通讯作者:
Martin, Olivier R.